An observational study in Parkinson Disease, sponsored by Federal University of Uberlandia. Completed at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Federal University of Uberlandia · Observational
Among 103 studies in Parkinson Disease with a site in Brazil — 19 open to participants now, 22 under way, 1 of them phase 3. Parkinson Disease · Brazil.
Among the 103 studies in Parkinson Disease with a site in Brazil, this one is one of 9 that started in 2023, is one of 8 observational ones, and was the 100th registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →19 of the 103 studies in Parkinson Disease with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Metodista de Piracicaba · Sites in Brazil
Ages 50–80
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 40+
Universidade Federal de Pernambuco · Sites in Brazil
Ages 40+
Hoffmann-La Roche · Sites in Brazil, United States, Australia and 14 more countries
Ages 50–85
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 749 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 96 across 1,086 observational studies indexed under Parkinson Disease.
Median enrollment 34 across the 95 interventional studies, 322 across the 8 observational. Of the 53 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 103 have an industry lead sponsor. The 10 most frequent:
Federal University of Uberlandia is the lead sponsor of 62 studies on the registry; 3 are open to participants now.
Federal University of Uberlandia has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Parkinson Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488026Universidade Federal de PernambucoEffects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease | 2026-11 |
| NCT07172698Federal University of Health Science of Porto AlegreEffects of a Multicomponent Protocol With Emphasis on Muscle Power Training on Bradykinesia in Individuals With Parkinson's Disease | 2026-12-01 |
| NCT06921122Hospital de Clinicas de Porto AlegreUse Of A Tongue Strength Training Device And Its Relationship With Speech In Patients With Parkinson's Disease | 2026-12-20 |
| NCT06815302Oregon Health and Science UniversityTURN-IT FOG: Improving Turning and Freezing of Gait in People With PD | 2026-12-31 |
| NCT07567599Federal University of Minas GeraisDeep Brain Stimulation in Parkinson's Disease: Motor and Functional Outcomes | 2027-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 103 studies in Parkinson Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational, longitudinal study with a control group, with the general objective of analysing the pattern of response of prefrontal cortex activity during motor and cognitive tasks in individuals with and without Parkinson's disease (PD) over 12 months. Prefrontal activity was recorded with a portable hemoencephalography (HEG) device placed on the forehead, in rest-task-rest blocks, while participants performed the Box and Block Test, the Nine-Hole Peg Test, the Trail Making Test (parts A and B) and spiral and sinusoid drawings. The assessments were repeated in up to 12 sessions, planned approximately monthly, and the tasks were video-recorded showing only the hands. Participants with PD were also assessed with the MDS-UPDRS Part III, the Hoehn \& Yahr scale and the PDQ-39 at the first and last sessions. Information that can identify the participants will be removed from the database before storage in a repository. The results will contribute to understanding how prefrontal activity relates to motor and cognitive performance in PD and how it changes over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group of subjects with Parkinson's disease
Neurological healthy subjects
Prefrontal hemoencephalography during the Box and Block Test
Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task.
Time frame: 12 months
Prefrontal hemoencephalography during the Nine-Hole Peg Test
Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task.
Time frame: 12 months
Prefrontal hemoencephalography during the Trail Making Test part A
Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task.
Time frame: 12 months
Prefrontal hemoencephalography during the Trail Making Test part B
Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task.
Time frame: 12 months
Prefrontal hemoencephalography during spiral and sinusoid drawing
Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task.
Time frame: 12 months
Box and Block Test
Number of blocks transferred in 60 seconds. Higher scores mean a better outcome.
Time frame: 12 months
Nine-Hole Peg Test
Time in seconds to place and remove nine pegs. Higher values mean a worse outcome.
Time frame: 12 months
Trail Making Test part A
Time in seconds to complete part A. Higher values mean a worse outcome.
Time frame: 12 months
Trail Making Test part B
Time in seconds to complete part B. Higher values mean a worse outcome.
Time frame: 12 months
Pen speed during drawing
Pen speed during spiral and sinusoid drawings, measured from the task videos, in percentage of the sheet size per second.
Time frame: 12 months
Drawing duration
Time in seconds to complete the spiral and sinusoid drawings, measured from the task videos.
Time frame: 12 months
Drawing smoothness (spectral arc length)
Spectral arc length (SPARC) of the pen trajectory during spiral and sinusoid drawings, measured from the task videos. Dimensionless; more negative values indicate less smooth movement.
Time frame: 12 months
MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III)
Clinical scale of motor signs of Parkinson's disease, applied to the experimental group. Each item is rated from 0 (normal) to 4 (severe); higher scores mean a worse outcome.
Time frame: First and last sessions (12 months)
Hoehn & Yahr scale
Stage of Parkinson's disease (1 to 5), applied to the experimental group. Higher stages mean a worse outcome.
Time frame: First and last sessions (12 months)
Parkinson's Disease Questionnaire (PDQ-39)
Disease-specific quality of life, applied to the experimental group. Summary index from 0 to 100; higher scores mean a worse outcome.
Time frame: First and last sessions (12 months)
Cognition (Mini-Mental State Examination)
Screening score from 0 to 30. Higher scores mean a better outcome.
Time frame: Baseline
Visual acuity
Visual acuity measured with the Snellen test
Time frame: Baseline
Plan to share: Yes — The data will be anonymised and stored in a safe and international platform (Zenodo - https://zenodo.org/communities/niats). Only data that cannot be used to identify the participants will be shared.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Starting 6 months after publication
Access criteria: Researchers that wish to have access to the data can request access at https://zenodo.org/communities/niats. Access will be granted for research purposes under a data sharing agreement.
Ran from Oct 2023 to primary completion in Jan 2026, 26 months.
Of 379 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's 26 months is below that.
Counting every sponsor, half of 439 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of Uberlandia